The immunosuppressive effects of cyclosporin A were tested in a DA (RT-1a) to Lewis (RT-1(1) rat renal allograft model, which represents a very strong histocompatibility barrier. Dose-response studies established that oral doses of 5 mg/kg/day or higher gave complete suppression of rejection, while oral doses of 2 mg/kg/day or lower were without effect. Intravenous administration of the drug approximately doubled its potency. Time studies showed that the period of administration was also critical, with a 7- or 14-day treatment course with 5 mg/kg/day orally giving prolonged graft survival, while a 4-day course was without effect. Large doses (up to 25 mg/kg/day orally) from day 4 after transplantation did not prolong graft survival, suggesting that cyclosporin A has no effect on an established rejection response. It was found that the lymphocytotoxin response to the graft was markedly suppressed by doses of cyclosporin A which maintained normal graft function, while lower doses had little or no effect on the lymphocytotoxin response. A cell-mediated immunity assay showed a substantial response, but one that was lower in amplitude from that of control animals. Histological study of 7th day allograft biopsies demonstrated essenti...Continue Reading
The effect of cyclosporine on mortality and renal function in living related pediatric kidney transplant recipients
In vivo mechanisms of alloreactivity--IV. Cyclosporine differentially impairs accumulation of donor-reactive CTL but not donor-reactive alloantibody in murine sponge matrix allografts
Indirect T cell allorecognition: a cyclosporin A resistant pathway for T cell help for antibody production to donor MHC antigens
Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection
Efficacy of azathioprine versus cyclosporine on kidney graft survival in transfused and nontransfused unmatched mongrel dogs
Importance of endogenous prostaglandins for the toxicity of cyclosporin A to rat endocrine and exocrine pancreas?
Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis
Skeletal effects of low-dose cyclosporin A in aged male rats: lack of relationship to serum testosterone levels
Formation of insulin-secreting, Sertoli-enriched tissue constructs by microgravity coculture of isolated pig islets and rat Sertoli cells
The use of spleen transplantation and cyclosporine treatment to induce unresponsiveness to pancreatic islet transplantation in rats
Effects of short-term cyclosporin-A on biomechanical properties of intact and fractured bone in the rat
The influence of cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis
Allogenic & Autologous Therapies
Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.